DTX 201

Drug Profile

DTX 201

Alternative Names: AAV-mediated Factor VIII gene therapy; DTX-201

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dimension Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia A

Most Recent Events

  • 07 Nov 2017 Dimension Therapeutics has been acquired by Ultragenyx Pharmaceutical
  • 27 Jun 2017 Dimension Therapeutics announces intention to submit IND application to the US FDA for Haemophilia A in early 2018
  • 27 Jun 2017 Dimension Therapeutics plans a clinical trial for Haemophilia A in USA in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top